Altay Therapeutics

Altay Therapeutics is dedicated to the creation of innovative small molecule drugs designed to combat chronic liver diseases, including liver fibrosis and liver cancer. A key member of our founding team, Dr. Osman Ozes, spearheaded the initial drug development program for Esbriet (Pirfenidone), which became the first FDA-approved treatment for lung fibrosis. Esbriet has since achieved blockbuster status, generating over $1 billion in annual revenue and exceeding $6 billion in total sales.

Leveraging a team with over 70 years of collective experience in small molecule drug development, Altay Therapeutics aims to replicate this success in the treatment of chronic liver diseases. This is a significant area of unmet need, affecting over 20 million Americans and representing a market opportunity exceeding $30 billion.

Our confidence in our approach is supported by compelling pre-clinical data from mouse models, demonstrating the efficacy of our novel small molecule in reducing liver fibrosis. Notably, our drug has shown the ability to reverse fibrotic tissue, restoring it to a healthy state.

Our current development strategy is focused on achieving a clinic-ready compound by the end of 2021, with the goal of initiating Phase I clinical trials by mid-2022.